4//SEC Filing
Bhat Laxminarayan 4
Accession 0001437749-24-029388
CIK 0001742927other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 5:01 PM ET
Size
8.9 KB
Accession
0001437749-24-029388
Insider Transaction Report
Form 4
Bhat Laxminarayan
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option (right to buy)
2024-09-15+77,843→ 77,843 total(indirect: By Spouse)Exercise: $1.20Exp: 2034-09-14→ Common Stock, par value $0.0001 per share (77,843 underlying) - Award
Stock Option (right to buy)
2024-09-15+158,451→ 158,451 totalExercise: $1.20Exp: 2034-09-14→ Common Stock, par value $0.0001 per share (158,451 underlying)
Footnotes (2)
- [F1]Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan.
- [F2]Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan.
Documents
Issuer
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CIK 0001742927
Entity typeother
Related Parties
1- filerCIK 0001818245
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 5:01 PM ET
- Size
- 8.9 KB